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The accuracy of estimated glomerular filtration rate (eGFR) equations in diabetes mellitus (DM) patients 
has been extensively questioned. We evaluated the performance of cystatin C-based equations alone 
or in combination with creatinine to estimate GFR in DM patients. A pRIsMA-compliant systematic 
review was performed in the MEDLINE and Embase databases, with “diabetes mellitus” and “cystatin 
C” as search terms. Studies comparing cystatin C-based eGFR equations with measured GFR (mGFR) in 
DM patients were eligible. Accuracies P10, P15, P20, and P30 indicated the proportion of eGFR results 
within 10, 15, 20, and 30% of mGFR. Single-arm meta-analyses were conducted, and the Quality of 
Diagnostic Accuracy Studies-II tool (QUADAS-2) was applied. Twenty-three studies comprising 7065 
participants were included, and 24 equations were analyzed in a broad range of GFRs. Meta-analyses 
were completed for 10 equations. The mean P30 accuracies of the equations ranged from 41% to 
87%, with the highest values found with both CKD-EPI equations. Mean P10-P15 achieved 35% in the 
best scenario. A sensitivity analysis to evaluate different mGFR methods did not change results. In 
conclusion, cystatin C-based eGFR equations represent measured GFR fairly at best in DM patients, with 
high variability among the several proposed equations.
According to the 2017 United States Renal Data System (USRDS) Annual Data Report, 40% of individuals living 
with chronic kidney disease (CKD) in the United States also had diabetes mellitus (DM)1. These data are consist-
ent with the results of the Brazilian Longitudinal Study of Adult Health (ELSA)-Brazil multicenter cohort survey, 
in which 42% of people with CKD had concomitant diabetes2.
As for more advanced stages, the 2015 European Renal Association − European Dialysis and Transplant 
Association (ERA-EDTA) Registry Annual Report found that, among patients starting renal replacement therapy, 
one-quarter had DM as their primary renal diagnosis3. A recent systematic review demonstrated substantial var-
iation in the incidence of end-stage renal disease (ESRD) among patients with diabetes, but a consistent finding 
was the excess risk of advanced kidney disease among this population when compared to non-diabetic individu-
als, ranging from 6- to 60-fold higher in diabetes4.
To detect diabetic kidney disease (DKD), up-to-date guidelines recommend annual screening with meas-
urement of urinary albumin excretion (UAE) in a spot urine sample and estimation of glomerular filtra-
tion rate (eGFR) with creatinine and/or cystatin C-based equations5. Specific use of serum cystatin C-based 
1Graduate Program in Medical Science: endocrinology, Universidade federal do Rio Grande do Sul (UfRGS), 
Porto Alegre, Brazil. 2internal Medicine Division, Hospital de clínicas de Porto Alegre (HcPA), Porto Alegre, Brazil. 
3endocrine Division, HcPA, Porto Alegre, Brazil. correspondence and requests for materials should be addressed to 
S.P.S. (email: silveirosandra@gmail.com)
Received: 4 July 2018
Accepted: 6 December 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts |          (2019) 9:1418  | https://doi.org/10.1038/s41598-018-38286-9
equations is recommended when creatinine-based equations yield questionable results, such as for patients with 
creatinine-based eGFR values between 45 and 60 mL/min/1.73 m2 and no other markers of kidney damage6.
The use of cystatin C-based equations is also favored in situations that affect serum creatinine levels, such as in 
patients with muscle mass loss secondary to limb amputations or neurological diseases7. In the DM population, it 
has been demonstrated that creatinine-based equations may markedly underestimate GFR, especially in patients 
with GFRs within normal or elevated ranges8–10. This worse performance seems to be related to analytical interfer-
ence of hyperglycemia on creatinine measurement and decreased sensitivity of creatinine to identify glomerular 
hyperfiltration8–11. In this context, there has been increasing interest in validating alternative markers. One such 
marker is cystatin C, an endogenous protein produced at a constant rate by nuclear cells, that is freely filtered by 
the glomerular membrane, being neither reabsorbed nor secreted in the kidney tubular system.
Several cystatin C-based equations have been developed for use in different populations. In patients with DM, 
a subset of studies has demonstrated superiority of these equations when compared to creatinine-based ones12,13. 
However, other studies disagree, demonstrating similar or even worse performance of cystatin C-based equa-
tions14–16. A recent proposal suggested the combined use of cystatin C- and creatinine-based equations, which 
seems to increase accuracy when compared to the use of either indicator alone17–19.
Within this context, the present study was designed to evaluate the accuracy of serum cystatin C-based equa-
tions, either alone or combined with serum creatinine, to estimate GFR in DM patients with a wide spectrum of 
renal function, by means of a systematic review of the literature and meta-analysis.
Methods
protocol and registration. This systematic review and meta-analysis follows the recommendations of 
the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) protocol20, and was reg-
istered in the International Prospective Register of Systematic Reviews (PROSPERO) with accession number 
CRD42018033197.
eligibility criteria. We included studies that compared the accuracy of serum cystatin C-based 
GFR-estimating equations to represent GFR measured (mGFR) by reference methods (125I-iothalamate, 
51Cr-EDTA, 99mTc-DTPA, inulin, iohexol) in patients with diabetes. Studies that evaluated patients with diabetes 
as a subgroup were included if there was available information.
The exclusion criteria were absence of data on the performance of the equation evaluated, animal studies, 
and review studies. There was no language or date restriction; articles written in languages other than English, 
Portuguese, and Spanish were considered eligible if they contained sufficient English-language information in the 
abstract, tables, and figures.
search strategy and study selection. We conducted a systematic search of the MEDLINE (via PubMed) 
and Embase databases, from inception to October 2017. Comprehensive search queries included descriptors 
(MeSH and Emtree) based on the expressions “diabetes mellitus” and “cystatin C” (index test). The complete 
search strategy is provided as a supplement.
Two independent reviewers (A.V.C. and M.Q.) assessed records for inclusion based on titles and abstracts. 
Abstracts that did not meet the inclusion criteria or that met the exclusion criteria were discarded. The remaining 
records and those whose abstracts did not provide sufficient information to decide upon their exclusion were 
selected for full-text evaluation, which was performed by the same reviewers independently. A third reviewer 
(S.P.S.) solved disagreements.
Data collection and extraction. Two investigators (A.V.C. and M.Q.) analyzed the selected studies and 
extracted data using a standardized system. The following information were obtained: first author, year of pub-
lication, study design, sample size, age distribution, mean mGFR, type of diabetes, cystatin C equation, ref-
erence method for mGFR, method of cystatin C measurement and whether it was traceable to the reference 
method, accuracy and correlation of the equation with measured GFR. All included equations are described in 
the supplement.
Risk of bias in individual studies and quality of meta-analysis. The risk of bias and the quality of 
studies were assessed with the Quality of Diagnostic Accuracy Studies-2 (QUADAS-2) tool21.
Diagnostic accuracy measures. Accuracy was defined as the percentage of GFR estimates within 10% 
(P10), 15% (P15), 20% (P20), 30% (P30), and 50% (P50) of mGFR. The coefficient of correlation between eGFR 
and mGFR was recorded.
synthesis of results and meta-analysis. The number of patients whose eGFR was within P10, P15, P20, 
and P30 of mGFR was entered into a single arm meta-analysis, carried out in CMA software version 3.0 to obtain 
an overall estimate of accuracy for each set of studies that used the same equation. We used the random effects 
model to incorporate heterogeneity, estimated by the inconsistency test (I2) proposed by Higgins et al.22. Cutoff 
points of 25 and 75% were used to classify heterogeneity as low, moderate, or high.
Additional analyses. In cases of moderate or high heterogeneity, we performed sensitivity analyses to eval-
uate the effect of different reference methods for mGFR.
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Results
The search strategy identified 1744 citations, of which 1345 were left after removal of duplicates. We excluded 
1258 articles after title and abstract screening, leaving 87 studies for full-text evaluation. Finally, 23 studies includ-
ing 7065 participants, with a broad range of GFR values, were selected for the systematic review. A flow diagram 
of study selection is presented in Fig. 1.
The selected articles were published between 2006 and 2016 and included 24 different equations (described in 
the Supplement). Nine studies evaluated only type 2 DM12–14,16,23–27, five investigated only type 1 DM28–32, and the 
remainder evaluated both or did not specify the type evaluated15,17,19,33–38. Among the methods used for measur-
ing serum cystatin C, eleven studies reported the use of immunonephelometry, five used immunoturbidimetry, 
one reported use of both methods, one used colorimetric immunoassay, one employed colloidal gold immuno-
assay, and three did not report the method used. The main characteristics of the studies are shown in Table 1.
Accuracy results (P10, P15, P20, P30, and P50) are shown in Table 2. Correlation ranged from 0.38 for the 
Berg equation to 0.92 for the CKD-EPI equation (creat/cyst) (See Supplementary Table S1).
Meta-analyses of accuracy could be performed for 10 equations: Arnal, CAPA, CKD-EPI (cyst), CKD-EPI 
(creat/cyst), MacIsaac, Perkins, Rule, Stevens (creat), Stevens (age), and Tan. We chose to pool P10-P15 accuracy 
values because of the small number of studies. The CKD-EPI equations were analyzed by P20 accuracy, as there 
was insufficient information on P10-P15. Meta-analysis of P30 accuracy was performed for all equations.
Figure 2 shows the forest plots of mean P10-P15 accuracies. The Tan equation had the highest mean P10-P15 
accuracy (35.2%), while the Perkins equation had the lowest (14.6%). The mean P20 accuracy of CKD-EPI equa-
tions was around 77%, whether with cystatin C alone or combined with creatinine (Fig. 3). Figure 4 illustrates 
the forest plots of P30 accuracy. Again, the Perkins equation had the lowest value (41.8%). The most accurate 
equations were CKD-EPI (creat/cyst), CKD-EPI (cyst), and Tan, with mean P30 accuracies of 87.6%, 83.6%, and 
77% respectively.
Two meta-analyses had moderate heterogeneity; none had high heterogeneity. Sensitivity analysis to evaluate 
the effect of different reference methods for mGFR in the cases of moderate heterogeneity did not change the 
results. Subanalyses with studies using only traceable cystatin C were performed. The only equations with enough 
studies to summarize the mean accuracies were the two CKD-EPI equations: mean P20 accuracy of 81.7% for 
CKD-EPI (creat/cyst), and mean P30 accuracies of 92.7% and 87.6% for CKD-EPI (creat/cyst) and CKD-EPI 
(cyst) respectively (See Supplementary Figs S1 and S2).
Finally, the overall quality of evidence as assessed by QUADAS-2 was good (See Supplementary Fig. S3). For 
the “index test” and “reference standard” domains, around 60% of the studies were considered to have an unclear 
risk of bias because they did not describe whether eGFR and mGFR results were interpreted without knowledge 
of each other. However, since both the index and reference tests are objective laboratory measurements, we con-
sidered that the risk of bias could be judged as low. Ten studies (40%) did not report the interval between cystatin 
measurement and isotopic measurement of GFR. There was low concern regarding applicability for 21 of the 23 
studies. For two studies, we had high concerns about applicability in one domain: one in the patient selection 
field, because all included subjects had cirrhosis, which could imply other interfering factor with renal function; 
and the other in the index test domain, since the equation used was validated in a cohort of individuals older than 
the included participants, although the authors used a conversion formula.
Discussion
The present systematic review evaluated 23 studies that analyzed the performance of cystatin C-based eGFR equa-
tions in patients with DM across a wide range of GFRs. In order to be a useful tool to predict GFR, an equation 
should present satisfactory accuracy, which encompasses the concepts of bias and precision. In practical terms, 
accuracy is described as the proportion of cases in which GFR estimations stand within 10% (P10), 15% (P15), 20% 
(P20), 30% (P30), and 50% (P50) of mGFR. The mean P30 accuracies of the equations analyzed herein varied widely, 
Figure 1. Study flowchart.
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from as low as 41% (with Perkins equation) to approximately 85% with the CKD-EPI equations, which offered 
the best performance. Either for clinical practice or for research purposes, we need GFR estimates that capture a 
large proportion of data that are within a meaningful boundary from target values – in this case measured GFR. 
Nonetheless, the boundary of ±30% of mGFR represents an unacceptably high margin of error. For example, in a 
patient with mGFR of 50 mL/min/1.73 m2, eGFR may vary from 35 to 65 mL/min/1.73 m2, which would represent 
different stages of CKD. When analyzing mean P10-P15 accuracies, a stricter comparison, proportions achieved 
35% in the best scenario; that is, eGFR varied within 10 to 15% in relation to mGFR in only 35% of cases. Thus, we 
can consider that even the best estimates provided by such equations are inadequate representations of mGFR.
The fact that the equations were developed in different populations might have contributed to their low accu-
racy. For example, Rule and Stevens equations were validated in patients with CKD, mainly of hypertensive ori-
gin. However, the MacIsaac and Perkins equations, both developed specifically in patients with type 2 diabetes, 
also presented inadequate performance. In addition, the same equation had divergent performances in different 
studies and within the same study according to mGFR levels. For example, MacIsaac, Arnal, and Perkins equa-
tions had much lower P10 accuracies in the study of Iliadis et al.14 than in Chudleigh et al.13. Also in the Iliadis 
study, Arnal, Rule, MacIsaac, Stevens (creat) and Stevens (age) equations performed better in patients with GFR 
between 30–59 mL/min/1.73 m2 when compared to GFR between 60–89 and above 90 mL/min/1.73 m2. In con-
trast, Tan and Perkins equations had higher accuracies when GFR was above 90 mL/min/1.73 m2. In the study 
of Bevc et al., CKD-EPI (creat/cyst) performed better in patients with stages 4 and 5 of CKD, with a mean P30 
accuracy of around 72%, compared to only 30% in patients with GFR above 90 mL/min/1.73 m2 12.
Some factors have been associated with variations in cystatin C measurement independently of renal func-
tion. Age, body mass index (BMI), smoking, hypertension, hyperthyroidism, malignancy, increased levels of 
C-reactive protein, and triglycerides are associated with higher levels of cystatin C39,40. In most studies included 
in this meta-analysis, detailed information about these possible influences was unavailable; therefore, they cannot 
be excluded as possible factors limiting the performance of the cystatin C-based equations.
Perhaps one important potential factor interfering with the performance of the equations might have been the 
method used for cystatin C measurement, especially the lack of traceability of some procedures. The most widely 
employed methods were immunonephelometry and immunoturbidimetry. The first certified reference mate-
rial for calibration of cystatin C-based assays, the so-called European Reference Material (ERM-DA471/IFCC), 





(mL/min/1.73 m2) Reference Method Equations
MacIsaac, 2006, Australia*† 126 89.2 ± 3 99mTc-DTPA MacIsaac
Beauviex, 2007, France*† 124 56.1 ± 35 51Cr-EDTA Arnal, Rule, MacIsaac, Tan
Rigalleau, 2008, France*† 124 56.1 ± 35 51Cr-EDTA Composite (creat/cyst)
Chudleigh, 2009, UK† 106 104.5 ± 20 51Cr-EDTA Perkins, Arnal, Rule, MacIsaac, Tan, Stevens (age), Stevens (creat)
Li H, 2010, China† 91 86.7 ± 27 99mTc-DTPA Perkins, MacIsaac, Rule, Stevens (creat), Ma
Cherney, 2010, Canada* 32 132.3 ± 19.7 Inulin MacIsaac
Didangelosb, 2010, Greece† 368 72 ± 22 51Cr-EDTA Stevens (age)
Iliadis, 2011, Greece† 448 73.4 ± 23 51Cr-EDTA Perkins, Arnal, Rule, MacIsaac, Stevens (age), Stevens (creat), Tan, Grubb, Tidman, Flodin
Bevc, 2012, Slovenia† 113 42.9 ± 30 51Cr-EDTA CKD-EPI (creat/cyst), Perkins
Inker, 2012, USA 
(development)*† 1726 68 ± 39
a 125I-Iothalamate, Iohexol, 51Cr-EDTA CKD-EPI (cyst)
Inker, 2012, USA (validation)*† 594 70 ± 41a 125I-Iothalamate, Iohexol, 51Cr-EDTA CKD-EPI (cyst)
Anderson, 2012, USA*† 224 49 ± 21a Urinary 125I-Iothalamate CRIC
Chenb, 2013, China† 279 69.8 ± 21 99mTc-DTPA Stevens, Rule
Iliadisb, 2013, Greece* 78 106.2 ± 10 51Cr-EDTA Tan
de Boer, 2014, USA* 1334 122.7 ± 21 125I-Iothalamate CKD-EPI (creat/cyst), CKD-EPI (cyst)
Maahs, 2014, USA* 15 84.1 ± 15 Iohexol CKD-EPI (creat/cyst), CKD-EPI (cyst)
Tsuda, 2014, Japan*† 40 68.1 ± 21 Inulin Japanese (creat/cyst), Japanese (cyst)
Fan, 2014, USA*† 594c 69.8 ± 41a 125I-Iothalamate, Iohexol, 51Cr-EDTA CKD-EPI (creat/cyst), CKD-EPI (cyst)
Mindikoglu, 2014, USA*† 22 83.6 ± 35a 125I-Iothalamate CKD-EPI (creat/cyst)
Vega, 2014, Spain*† 31 53.48 ± 34 99mTc-DTPA Hoek
Perrin, 2015, Sweden* 104 128 (111–143) Inulin Schwartz (cyst), Schwartz (creat/cyst), Inker (cyst), Inker (creat/cyst), Capa, Berg
Machadob, 2015, Brazil† 84 104 ± 27 51Cr-EDTA CKD-EPI (creat/cyst), CKD-EPI (cyst), CAPA
Barr, 2016, Australia† 216 104 (83–122)a Iohexol CKD-EPI (creat/cyst), CKD-EPI (cyst)
Kakaletsisb, 2016, Greece† 192 NR 51Cr-EDTA CKD-EPI (creat/cyst), CKD-EPI (cyst)
Table 1. Characteristics of the included studies. *Type 1 diabetes mellitus. †Type 2 diabetes mellitus. aData 
from overall study population, not the subgroup of diabetic patients. bPublished in conference annals. cSame 
population of the validation subgroup of Inker et al. NR, not reported.
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Grubb Iliadis 20.9 69.1
Tidman Iliadis 13.2 40.1
Flodin Iliadis 16.5 43.4
Ma Li H — 61.5
Schwartz (cyst) Perrin 7 53
Schwartz (creat/cyst) Perrin 10 51
Inker (cyst) Perrin 42 84
Inker (creat/cyst) Perrin 45 94
Berg Perrin 40 86
Composite (creat/cyst) Rigalleau — —
Continued
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methods, since most were conducted before development of the reference material. However, even after analyz-
ing only the equations that used traceable methods, performance did not change substantially. Therefore, bias 
remains a major source of uncertainty, as manufacturers still have to work to improve calibration procedures42.
Equation Study P10 (%) P30 (%)
Japanese (creat/cyst) Tsuda — —
Japanese (cyst) Tsuda — —
Hoek Vega — —
CRIC Anderson — 83
Table 2. Accuracy results (P10 and P30) for the included equations. *Published in conference annals. †Bevc: 
accuracy according to stage of GFR (1–5).
Figure 2. Forest plots of mean P10–15 accuracies using random effects meta-analysis.
Figure 3. Forest plots of mean P20 accuracies using random effects meta-analysis.
www.nature.com/scientificreports/
7Scientific RepoRts |          (2019) 9:1418  | https://doi.org/10.1038/s41598-018-38286-9
There is undeniable heterogeneity among the different equations developed for GFR estimation. Some use 
gender, while others do not12,14,16,19,28,32,35–38. Even skin color, a highly controversial issue, has been included in 
some formulas. Furthermore, since the equations are obtained from regression models, validation for different 
populations is clearly necessary, contemplating varied ranges of GFR and BMI, as well as different types of renal 
disease.
Currently, Kidney Disease Improving Global Outcomes (KDIGO) recommends the use of cystatin C-based 
equations whenever eGFR calculated with creatinine-based equations is 45–60 mL/min (borderline normality) 
in the absence of other evidence of kidney damage6. It is well known that, unlike creatinine, cystatin C is not 
affected by muscle mass, and, therefore, would not be influenced by gender, malnutrition, amputations, or any 
condition that affects creatinine18,43. The use of combined cystatin-creatinine equations has been gaining ground, 
since each analyte should theoretically balance out the limitations of the other. We had enough data to perform 
meta-analyses for only two combined equations: Stevens (creat) and CKD-EPI (creat/cyst). The Stevens combined 
equation had similarly poor results (mean P10–15 of 28%) to equations using cystatin C only. The CKD-EPI 
(creat/cyst) equation had the same mean P20 accuracy (77%) as CKD-EPI (cyst) equation. Therefore, in the 
present meta-analysis, this practice did not appear to provide any clear advantage over isolated use of cystatin 
C-based equations.
The growing interest in the use of cystatin C in diabetic patients originated in studies which reported encour-
aging predictive ability of cystatin C to anticipate cardiovascular and renal outcomes in this population – in some 
cases demonstrating a remarkable power to predict mortality44–47. Two meta-analyses in patients with DM, using 
receiver operating characteristic (ROC) curve data analysis, suggested that cystatin C could be a more sensitive 
Figure 4. Forest plots of mean P30 accuracies using random effects meta-analysis.
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marker for the detection of renal disease than creatinine48, as well as an early predictor of DKD49. However, these 
two studies employed different concepts from the present meta-analysis, using serum cystatin C alone as an indi-
cator, not its transposition into equations for estimation of GFR. To the best of our knowledge, this was the first 
meta-analysis to assess the performance of cystatin C-based eGFR equations in diabetic patients by evaluating 
their accuracy, as recommended in the literature.
A recent mini-review evaluated the errors of estimated - creatinine or cystatin C based equations, alone or in 
combination - versus true GFR in patients with DM50. The proportion of eGFR values within ±30% (P30) ranged 
from 21% to 90%, highlighting the unacceptable high variability of the equations. In some series, 35% of the cases 
would be misclassified according to CKD stages. These findings reemphasize the perspective that P30 is an exces-
sively high limit to validate a formula, and P10 would be a more representative test.
Although the present meta-analysis primarily focused on cystatin C-equations accuracy in diabetes, it is 
worthwhile to mention some aspects of the most widespread used creatinine-centered equations in this subset of 
patients. A recent meta-analysis compared MDRD with CKD-EPI creatinine-based equation, evaluating 48 stud-
ies (8 in diabetes), and showed that both equations underestimated mGFR, although CKD-EPI gave more accu-
rate estimates51. This underestimation seems to be indeed more noticeable in patients with diabetes, even with the 
use of CKD-EPI equation8,9,50. In this sense, cystatin C-based equations would fulfill a gap. A large European mul-
ticenter study concluded that, overall, the addition of cystatin C improved precision of the combined equations 
compared with their creatinine equation counterparts52. However, once more in the diabetes scenario, cystatin 
C-based equations do not seem to outperform creatinine equations26,53.
Many studies included in this systematic review assessed correlation coefficients between estimated and meas-
ured GFR. These coefficients varied widely, from weak to relatively robust. Nevertheless, correlation is not the 
most appropriate statistical procedure for comparison between methods; Bland–Altman agreement analysis is the 
recommended exploratory method54. In addition, specific statistics of agreement for continuous variables - the 
concordance correlation coefficient (CCC), the total deviation index (TDI), and the coverage probability (CP) 
- have been increasingly used. CCC combines accuracy and precision, and it is scored from 0 to 1; TDI captures 
a huge proportion of data within a boundary for allowed differences between estimations and measurements. 
Regrettably, these analyses are still underused, and the studies included in the present meta-analysis did not show 
this kind of investigation55.
Some limitations of our work must be taken into account. First, there are no reliable methods to assess the risk 
of publication bias in systematic reviews of observational studies, and, despite our thorough literature search, the 
potential for such bias in the present study is unknown. Second, combining the results of P10 and P15 is debata-
ble. Notwithstanding, we chose to put it together because of the scant data from individual studies to do separate 
analyzes. Third, despite the use of random-effects meta-analysis, some of the observed heterogeneity could not 
be explained by subgroup meta-analysis, and is likely to reflect real differences in studied populations or in the 
methods employed among different studies. This limits the external validity of pooled effect-size estimates. These 
limitations notwithstanding, we believe we were able to effectively find and summarize the current evidence on 
the accuracy of serum cystatin C-based equations to estimate GFR in diabetic patients.
In conclusion, the use of serum cystatin C in equations to estimate GFR, either alone or in association with 
serum creatinine, represent measured GFR fairly at best in DM patients, with high variability among the several 
proposed equations. Given the ample heterogeneity of existing equations used to estimate GFR and the preceding 
use of non-traceable cystatin C assays, future studies following guidelines for validation of diagnostic methods 
should be conducted to develop new equations with greater external validity.
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